Baird Financial Group Inc. cut its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 7.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 354,237 shares of the biotechnology company's stock after selling 28,373 shares during the quarter. Baird Financial Group Inc. owned approximately 0.63% of Repligen worth $50,989,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the business. UMB Bank n.a. lifted its stake in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Repligen during the fourth quarter valued at approximately $216,000. Van ECK Associates Corp increased its holdings in shares of Repligen by 7.8% in the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock valued at $6,078,000 after acquiring an additional 3,066 shares during the period. Stephens Investment Management Group LLC grew its stake in Repligen by 7.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock valued at $77,267,000 after purchasing an additional 37,057 shares during the last quarter. Finally, Artemis Investment Management LLP raised its stake in shares of Repligen by 18.4% during the 4th quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company's stock worth $22,143,000 after acquiring an additional 23,905 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Insider Buying and Selling
In related news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is owned by insiders.
Repligen Stock Down 2.7 %
RGEN traded down $3.52 during trading on Wednesday, hitting $126.88. The company had a trading volume of 1,379,904 shares, compared to its average volume of 724,015. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The business has a 50-day moving average of $136.86 and a 200-day moving average of $145.74. The company has a market cap of $7.12 billion, a PE ratio of -248.78, a P/E/G ratio of 4.54 and a beta of 1.21.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period last year, the firm posted $0.28 earnings per share. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. As a group, analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have commented on the company. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research report on Tuesday, April 29th. JPMorgan Chase & Co. lowered their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Evercore ISI began coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. Finally, StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Monday, April 28th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.
Read Our Latest Stock Report on Repligen
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
